Reshma Kewalramani
CEO & President at Vertex Pharmaceuticals Incorporated · b. 1972
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Vertex Pharmaceuticals Incorporated, 3 years.
Chief executive roles
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 35% of the scoring weight is on file.
- Revenue growth 20%
- 99
- Earnings growth 15%
- 97
19.3% a year in revenue
22.6% a year in earnings per share
35% of the scoring weight is on file. Figures cover December 2019 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Vertex Pharmaceuticals Incorporated May 13, 202699.6%
-
Vertex Pharmaceuticals Incorporated May 14, 202599.8%
-
Vertex Pharmaceuticals Incorporated May 15, 202499.7%
-
Ginkgo Bioworks Holdings Inc. June 16, 202397.3%
-
Vertex Pharmaceuticals Incorporated May 17, 202399.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 6, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −11,866 | $531.53 | $6,307,135 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −400 | $479.75 | $191,900 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −120 | $481.50 | $57,780 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −240 | $482.84 | $115,882 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −2,510 | $487.13 | $1,222,696 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −3,278 | $488.27 | $1,600,549 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −460 | $489.32 | $225,087 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −2,725 | $490.54 | $1,336,722 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −949 | $491.30 | $466,244 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −2,520 | $493.29 | $1,243,091 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −3,498 | $494.33 | $1,729,166 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −15,580 | $495.38 | $7,718,020 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −5,995 | $496.16 | $2,974,479 |
| Feb 27, 2026 | Vertex Pharmaceuticals Incorporated | Open-market sale | −1,725 | $496.95 | $857,239 |
| Feb 24, 2026 | Vertex Pharmaceuticals Incorporated | Shares withheld for tax | −4,981 | $485.11 | $2,416,333 |
Questions about Reshma Kewalramani
What boards is Reshma Kewalramani on?
Reshma Kewalramani sits on the boards of Ginkgo Bioworks Holdings Inc. and Vertex Pharmaceuticals Incorporated.
What company is Reshma Kewalramani the CEO of?
Reshma Kewalramani has been CEO & President of Vertex Pharmaceuticals Incorporated since April 2020.
How long has Reshma Kewalramani served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.